BD ONCLARITY™ HPV Test for the FDA Approved HPV assay for extended genotyping Extended genotyping supports risk stratification and persistence monitoring to guide patient management Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but their prevalence is declining as vaccination rates increase Genotypes 31, 33, 58 have a CIN3+ risk similar to genotype 18, but 51, 35, 39, 68, 56, 59, 66 have a much lower risk